New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
17:35 EDTPAH, AIV, AGN, HME, BEAM, GGP, PGPershing Square gives quarterly update on stakes
NEW STAKES: Platform Specialty Products (PAH), Apartment Investment and Management (AIV), Allergan (AGN), and Home Properties (HME). INCREASED STAKES: None. DECREASED STAKES: Beam (BEAM). LIQUIDATED STAKES: General Growth Properties (GGP), and Procter & Gamble (PG).
News For PAH;AIV;AGN;HME;BEAM;GGP;PG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 20, 2014
07:17 EDTPAHPlatform Specialty Products to acquire Arysta LifeScience for $3.51B
Subscribe for More Information
07:16 EDTAGNAmerican Academy of Ophthalmology to hold annual meeting
AAO Annual Meeting 2014 is being held in Chicago on October 18-21.
06:28 EDTAGNAllergan price target raised to $210 from $190 at Citigroup
Subscribe for More Information
October 17, 2014
09:47 EDTAGNValeant will not raise Allergan bid ahead of record date, CNBC reports
Valeant (VRX) will not raise its hostile takeover bid for Allergan (AGN) ahead of the record date for the vote, CNBC's David Faber reports. Allergan (AGN) is not currently in takeover talks with Actavis (ACT), Faber added.
09:45 EDTAGNAllergan not in deal talks with Actavis, CNBC reports
09:43 EDTAGNValeant not going to raise Allergan bid ahead of meeting, CNBC reports
Subscribe for More Information
October 16, 2014
15:10 EDTPGAmerican College of Gastroenterology to hold annual meeting
ACG Annual Scientific Meeting 2014 to be held in Philadlephia, PA on October 17-22.
12:42 EDTAGNAckman believes Allergan, Valeant merger likely, CNBC reports
Subscribe for More Information
12:38 EDTAGNAckman says Allergan CEO manipulated Valeant shares, CNBC reports
Subscribe for More Information
08:58 EDTAGNAllergan was pressured by AbbVie news, says BMO Capital
Subscribe for More Information
07:23 EDTAGNIBF Conferences to hold a summit
Ophthalmology Innovation Summit is being held in Chicago on October 16.
October 15, 2014
15:00 EDTAGNShire-Allergan, AbbVie-Pfizer deals possible if merger scrapped, Bloomberg says
Subscribe for More Information
13:07 EDTAGNAllergan seeing arb-related selling pressure, says BMO Capital
Subscribe for More Information
October 14, 2014
10:08 EDTPGProcter & Gamble: There is no doubt we are in a stretch of global volatility
The company said there is a high amount of volatility both politically and economically. The company said it is "trying its best" and that they're "on it."
09:26 EDTPGProcter & Gamble sees significant savings opportunities
The company plans to create a new P&G over the next 18-24 months that will consist of 70-80 brands organized in a dozen businesses. The company plans to reduce waste, and to have a North Aerican supply chain redesign that will see fewer, multi-category plants and more common manufacturing platforms. Comments taken from P&G Annual Meeting of Shareholders.
06:03 EDTAGNMarket overreacted to new Irish tax rules, says BMO Capital
BMO Capital believes the market may have overreacted yesterday to the report that Ireland is eliminating the "Double Irish" tax loophole. The firm says Allergan (AGN) confirmed that it incorporated potential changes to Irish tax law in its recently raised earnings guidance while Mallinckrodt (MNK) said it does expect the new tax structure to have an immediate impact. BMO views yesterday's pullback in shares of Allergan, Mallinckrodt and Actavis (ACT) as an overreaction.
October 13, 2014
10:08 EDTAIVOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:14 EDTAIVAimco upgraded at Raymond James
As previously reported, Raymond James upgraded Aimco to Strong Buy from Market Perform. The firm upgraded shares based on the substantial increase in portfolio quality over the past year, an accretive re-development program, cap rate compression in key markets, and visibility to an investment grade rating. Price target raised to $39.
07:21 EDTAIVAimco upgraded to Strong Buy from Market Perform at Raymond James
Subscribe for More Information
06:39 EDTAGNAllergan takeout value at or above $210 per share, says Leerink
Leerink believes Allergan's takeover value is now at or above $210 per share given the company's recent execution. After speaking with management, the firm says Allergan's upside in Q3 was driving by fundamentals, not cost cuts. It continues to view the "most likely and straightforward outcome" for Allergan as being an outright sale of the company. Leerink raised its price target for shares to $215 from $184 and keeps an Outperform rating on Allergan.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use